Literature DB >> 18981324

Hypertension in response to chronic reductions in uterine perfusion in pregnant rats: effect of tumor necrosis factor-alpha blockade.

Babbette LaMarca1, Josh Speed, Lillian Fournier, Sara A Babcock, Hunter Berry, Kathy Cockrell, Joey P Granger.   

Abstract

Reductions in uterine perfusion pressure (RUPP) in pregnant rats is associated with increased tumor necrosis factor-alpha (TNF-alpha). This study was designed to determine the role of endogenous TNF-alpha in mediating changes in arterial pressure and endothelin-1 (ET-1) in RUPP rats. To achieve this goal we examined the effect of RUPP in the presence and absence of a TNF-alpha-soluble receptor, etanerecept (0.4 mg/kg). Mean arterial pressure increased from 102+/-1 mm Hg in normal pregnant (NP) rats to 134+/-3 mm Hg (P<0.05) in RUPP rats. Serum TNF-alpha increased to 40+/-7.6 pg/mL in RUPP rats (n=24) versus 14.8+/-3.3 pg/mL (n=16; P<0.05) in NP rats. Administration of etanerecept decreased TNF-alpha in RUPP rats (n=20) to 17.2+/-3 pg/mL and mean arterial pressure to 118+/-2 mm Hg (P<0.05). Tissue ET-1 decreased in etanerecept-treated RUPP rats compared with control RUPP rats. The direct effect of TNF-alpha blockade on endothelial activation in response to placental ischemia was examined in human umbilical vein endothelial cells. ET-1 secreted from human umbilical vein endothelial cells treated with RUPP serum was 59.2+16 pg/mg and decreased when etanerecept was added to the medium with RUPP serum (7.60+/-0.77 pg/mg), as well as in response to serum from etanerecept-treated RUPP rats (7.30+/-0.55 pg/mg; P<0.001). ET-1 secreted from human umbilical vein endothelial cells was 15.6+/-2 pg/mg when treated with NP serum. These data support the hypothesis that endogenous TNF-alpha is an important stimulus for ET-1 in response to placental ischemia and is important in mediating endothelial cell activation and hypertension during pregnancy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18981324      PMCID: PMC2788766          DOI: 10.1161/HYPERTENSIONAHA.108.120881

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  25 in total

1.  Inflammatory cytokines, vascular function, and hypertension.

Authors:  Joey P Granger
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2004-06       Impact factor: 3.619

Review 2.  Tumour necrosis factor-alpha blockade: a new era for effective management of rheumatoid arthritis.

Authors:  K Hamilton; E W Clair
Journal:  Expert Opin Pharmacother       Date:  2000-07       Impact factor: 3.889

3.  Effect of TNF-alpha--converting enzyme inhibitor on insulin resistance in fructose-fed rats.

Authors:  Nobuhiko Togashi; Nobuyuki Ura; Katsuhiro Higashiura; Hideyuki Murakami; Kazuaki Shimamoto
Journal:  Hypertension       Date:  2002-02       Impact factor: 10.190

4.  Tumor necrosis factor antagonism with etanercept improves systemic endothelial vasoreactivity in patients with advanced heart failure.

Authors:  S Fichtlscherer; L Rössig; S Breuer; M Vasa; S Dimmeler; A M Zeiher
Journal:  Circulation       Date:  2001-12-18       Impact factor: 29.690

5.  The effects of TNF alpha inhibition on plasma fibrinolytic balance in patients with chronic inflammatory rheumatical disorders.

Authors:  M Agirbasli; N Inanc; O A Baykan; H Direskeneli
Journal:  Clin Exp Rheumatol       Date:  2006 Sep-Oct       Impact factor: 4.473

6.  TNF-alpha inhibition reduces renal injury in DOCA-salt hypertensive rats.

Authors:  Ahmed A Elmarakby; Jeffrey E Quigley; John D Imig; Jennifer S Pollock; David M Pollock
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2007-11-07       Impact factor: 3.619

Review 7.  [Autoimmune aspects of treatment with TNF-alpha inhibitors].

Authors:  Bogdan Kolarz; Bozena Targońska-Stepniak; Dorota Darmochwał-Kolarz; Maria Majdan
Journal:  Postepy Hig Med Dosw (Online)       Date:  2007-08-28       Impact factor: 0.270

8.  Reduced uterine perfusion pressure (RUPP) model for studying cardiovascular-renal dysfunction in response to placental ischemia.

Authors:  Joey P Granger; B Babbette D LaMarca; Kathy Cockrell; Mona Sedeek; Charles Balzi; Derrick Chandler; William Bennett
Journal:  Methods Mol Med       Date:  2006

Review 9.  Vascular mechanisms of increased arterial pressure in preeclampsia: lessons from animal models.

Authors:  Raouf A Khalil; Joey P Granger
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2002-07       Impact factor: 3.619

Review 10.  Recent Insights into the pathogenesis of pre-eclampsia.

Authors:  J M Roberts; K Y Lain
Journal:  Placenta       Date:  2002-05       Impact factor: 3.481

View more
  92 in total

1.  IL-6-induced pathophysiology during pre-eclampsia: potential therapeutic role for magnesium sulfate?

Authors:  Babbette Lamarca; Justin Brewer; Kedra Wallace
Journal:  Int J Interferon Cytokine Mediat Res       Date:  2011-07-01

2.  17-hydroxyprogesterone caproate significantly improves clinical characteristics of preeclampsia in the reduced uterine perfusion pressure rat model.

Authors:  Lorena M Amaral; Denise C Cornelius; Ashlyn Harmon; Janae Moseley; James N Martin; Babbette LaMarca
Journal:  Hypertension       Date:  2014-11-03       Impact factor: 10.190

3.  Recent insights into the pathophysiology of preeclampsia.

Authors:  Eric M George; Joey P Granger
Journal:  Expert Rev Obstet Gynecol       Date:  2010-09-01

4.  The role of immune activation in contributing to vascular dysfunction and the pathophysiology of hypertension during preeclampsia.

Authors:  B Lamarca
Journal:  Minerva Ginecol       Date:  2010-04

5.  Hypertension in response to CD4(+) T cells from reduced uterine perfusion pregnant rats is associated with activation of the endothelin-1 system.

Authors:  Kedra Wallace; Sarah Novotny; Judith Heath; Janae Moseley; James N Martin; Michelle Y Owens; Babbette LaMarca
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-05-30       Impact factor: 3.619

Review 6.  Genetic, immune and vasoactive factors in the vascular dysfunction associated with hypertension in pregnancy.

Authors:  Sajjadh M J Ali; Raouf A Khalil
Journal:  Expert Opin Ther Targets       Date:  2015-08-17       Impact factor: 6.902

7.  Heme oxygenase-1 is a potent inhibitor of placental ischemia-mediated endothelin-1 production in cultured human glomerular endothelial cells.

Authors:  Bhavisha A Bakrania; Frank T Spradley; Simon C Satchell; David E Stec; John M Rimoldi; Rama S V Gadepalli; Joey P Granger
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2017-12-06       Impact factor: 3.619

8.  Placental hypoxia-induced alterations in vascular function, morphology, and endothelial barrier integrity.

Authors:  Philippe Vangrieken; Alex H V Remels; Salwan Al-Nasiry; Aalt Bast; Ger M J Janssen; Ulrike von Rango; Daan Vroomans; Yannick C W Pinckers; Frederik J van Schooten; Paul M H Schiffers
Journal:  Hypertens Res       Date:  2020-07-30       Impact factor: 3.872

9.  Chronic hyperleptinemia results in the development of hypertension in pregnant rats.

Authors:  Ana C Palei; Frank T Spradley; Joey P Granger
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-03-11       Impact factor: 3.619

Review 10.  Bioactive factors in uteroplacental and systemic circulation link placental ischemia to generalized vascular dysfunction in hypertensive pregnancy and preeclampsia.

Authors:  Dania A Shah; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2015-04-24       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.